Beatriz Díaz‐Pollán

ORCID: 0000-0002-7241-4208
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • COVID-19 Clinical Research Studies
  • SARS-CoV-2 and COVID-19 Research
  • HIV/AIDS drug development and treatment
  • Long-Term Effects of COVID-19
  • HIV Research and Treatment
  • Clostridium difficile and Clostridium perfringens research
  • Antibiotic Resistance in Bacteria
  • Microscopic Colitis
  • HIV/AIDS Research and Interventions
  • Antimicrobial Resistance in Staphylococcus
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Pneumonia and Respiratory Infections
  • Antibiotics Pharmacokinetics and Efficacy
  • Bacterial Infections and Vaccines
  • Nosocomial Infections in ICU
  • Tuberculosis Research and Epidemiology
  • Urinary Tract Infections Management
  • Helicobacter pylori-related gastroenterology studies
  • Antibiotic Use and Resistance
  • Fungal Infections and Studies
  • Bacterial Identification and Susceptibility Testing
  • COVID-19 and healthcare impacts
  • HIV-related health complications and treatments
  • Respiratory viral infections research

Hospital Universitario La Paz
2014-2024

Hospital La Paz Institute for Health Research
2021-2024

Instituto de Salud Carlos III
2001-2024

Centro de Investigación Biomédica en Red
2022-2024

Centre for Biomedical Network Research on Rare Diseases
2022-2024

Instituto de Investigación Biomédica de Salamanca
2024

Centro de Investigación Biomédica en Red de Cáncer
2024

Universidad Autónoma de Madrid
2021

Universidad Alfonso X el Sabio
2017

Universidad Autónoma de Ciudad Juárez
2016

Jesús Rodríguez‐Baño Jerónimo Pachón Jordi Carratalá Pablo Ryan Inmaculada Jarrín and 95 more María Yllescas José Ramón Arribas Juan Berenguer Esther Aznar Muñoz Pedro Gil Divasson Patricia González Muñiz Clara Aguirre Marta Díaz‐Menéndez Fernando Calle Marta Arsuaga Vicente Elena Trigo Esteban Ignacio Valero Rosa de Miguel Buckley Julen Cadiñanos Beatriz Díaz‐Pollán Luz Martín‐Carbonero Juan Carlos Ramos Ramos Belén Loeches Yagüe Rocío Montejano Juan González‐García Julio García‐Rodríguez Juan Berenguer Margarita Ramírez Isabel Gutiérrez Francisco Tejerina Teresa Aldámiz‐Echevarría Cristina Díez Chiara Fanciulli Leire Pérez‐Latorre Blanca Pinilla Juan Carlos López Ana Such Díaz Elena Álvaro Alonso Juan Torres Macho Guillermo Cuevas Eva Jiménez Fátima Brañas Baztán Jorge Valencia de la Rosa Mario Pérez Inés Fernández Jiménez Gemma Muñiz Nicolás Antonia Sepúlveda Berrocal Alberto Gato Díez María Pilar Toledano Sierra María Paz García Butenegro Ana Isabel Peláez Ballesta Elena Morcillo Rodríguez Isidoro Fernández Romero Cristina Peláez Ballesta María Isabel Guirado Torrecillas Josune Goikoetxea Elena Bereciartua Bastarrica Laura Guío Carrión Regino Rodríguez Marta Ibarrola Hierro Isabel Hernández Inés Pérez Zapata Sergio Román Soto Mohamed Kallouchi Juan Ramón Domínguez Vicent Rafae Silvariño Fernández Jon Ugalde Espiñeira Ainhoa Sanjuan López Silvia García Martínez Mikel Temprano Gogenola Víctor Asensi Silvia Suárez Lucia Suárez Carmen Yllera María Rivas-Carmenado Alberto Romero-Palacios Jesús Ruiz Aragón Patricia Jiménez Aguilar Ma Luisa Fernández Ávila Rosario Castilla Ortiz Vanesa Alende Castro Cristina Pérez García Marta Fernández Morales María Lorena María Valle Feijoo Begoña Rodríguez Ferreira Joan Gómez‐Junyent Judit Villar-García Inmaculada López-Montesinos Itziar Arrieta‐Aldea Abora Rial‐Villavecchia Elisa García Vázquez Aychel Elena Roura Piloto Encarnación Moral Escudero Alicia Hernández Torres Helena Iglesias David Vinuesa García Clara Martínez Montes Francisco Javier de la Hera Fernández Francisco Anguita-Santos Andrés Ruiz Sancho Vicens Diaz–Brito

ObjectivesThe objective of this study was to estimate the association between tocilizumab or corticosteroids and risk intubation death in patients with coronavirus disease 19 (COVID-19) a hyperinflammatory state according clinical laboratory parameters.MethodsA cohort performed 60 Spanish hospitals including 778 COVID-19 data indicative state. Treatment mainly tocilizumab, an intermediate-high dose (IHDC), pulse (PDC), combination therapy, no treatment. Primary outcome death; follow-up 21...

10.1016/j.cmi.2020.08.010 article EN cc-by-nc-nd Clinical Microbiology and Infection 2020-08-27
Belén Gutiérrez‐Gutiérrez María Dolores del Toro Alberto M. Borobia Antonio J. Carcas Inmaculada Jarrín and 95 more María Yllescas Pablo Ryan Jerónimo Pachón Jordi Carratalá Juan Berenguer José Ramón Arribas Jesús Rodríguez‐Baño Esther Aznar Muñoz Pedro Gil Divasson Patricia González Muñiz Clara Aguirre Pilar Retamar Adoración Valiente Luis Eduardo López-Cortés Jesús Sojo-Dorado José María Bravo-Ferrer Elena Salamanca Zaira R. Palacios‐Baena Patricia Pérez‐Palacios M. Gandullo-Moro Rocío Ruíz-Hueso Natalia Moya-González Agustín Valido-Morales María Pavón-Masa Marta Díaz‐Menéndez Fernando Calle Marta Arsuaga Vicente Elena Trigo Esteban Rosa de Miguel Buckley Julen Cadiñanos Carmen Busca Rafael Micán Marta Mora-Rillo Belén Loeches Yagüe José I. Bernardino Julio García‐Rodríguez Rocío Montejano Beatriz Díaz‐Pollán Juan Carlos López Margarita Ramírez-Schacke Isabel Gutiérrez Francisco Tejerina Teresa Aldámiz‐Echevarría Cristina Díez Chiara Fanciulli Leire Pérez‐Latorre F Parras Pilar Catalán María E. García-Leoni Isabel Pérez-Tamayo Luís Puente‐Maestu Jamil Cedeño A. Such-Díaz Elena Alba Álvaro-Alonso Elsa Izquierdo-García Juan Torres‐Macho Guillermo Cuevas Helena Notario B. Mestre-Gómez Eva Jiménez Inés Fernández-Jiménez Ana Josefa Tebar-Martínez Fátima Brañas Jorge Valencia Mario Pérez Marta Alvarado Gabriela Abelenda-Alonso Carmen Ardanuy Alba Bergas Guillermo Cuervo M.Á. Domínguez Miguel Fernández-Huerta Carlota Gudiol Laia Lorenzo-Esteller Jordí Niubó Sandra Pérez‐Recio Daniel Podzamczer Miquel Pujol Alexander Rombauts Núria Trullen José Miguel Cisneros Cristina Amodeo Pedro Camacho Núria Espinosa Manuel García‐Gutiérrez Luis Jara‐Palomares Rocío González-León José Molina Maria Martin María Paniagua Manuel Poyato Borrego Ángel Rodríguez-Villodres Zaida Ruiz de Azua Celia Salamanca Mo Antonia Sepúlveda Berrocal

10.1016/s1473-3099(21)00019-0 article EN other-oa The Lancet Infectious Diseases 2021-02-24
Marius Trøseid José Ramón Arribas Lambert Assoumou Aleksander Rygh Holten Julien Poissy and 95 more Vida Terzić Fulvia Mazzaferri Jesús Rodríguez‐Baño Joe Eustace Maya Hites Michael Joannidis José Artur Paiva Jean Reuter Isabel Püntmann Thale D.J.H. Patrick-Brown Elin Westerheim Kateřina Nezvalová‐Henriksen Lydie Béniguel Tuva B. Dahl Maude Bouscambert Monika Halanova Zoltán Péterfi Sotirios Tsiodras Michael Rezek Matthias Briel Serhat Ünal Martin Schlegel Florence Ader Karine Lacombe Cecilie Delphin Amdal S. Vicente Rodrigues Kristian Tonby Alexandre Gaudet Lars Heggelund Joy Mootien Asgeir Johannessen Jannicke Horjen Møller Beatriz Díaz‐Pollán Anders Tveita Anders Benjamin Kildal Jean‐Christophe Richard Olav Dalgård Victoria Charlotte Simensen Aliou Baldé Lucie de Gastines Marta del Álamo Burç Aydın Fridtjof Lund‐Johansen Mary‐Anne Trabaud Alpha Diallo Bente Halvorsen John-Arne Røttingen Evelina Tacconelli Yazdan Yazdanpanah Inge Christoffer Olsen Dominique Costagliola Anne Ma Dyrhol‐Riise Birgitte Stiksrud Synne Jenum Magnhild E. Macpherson Nikolai Ravn Aarskog Kjerstin Røstad Linda Gail Skeie Åsne Dahl Jeanette Konstance Steen Sarah Nur Filip M. Segers Katrine Andersen Korsan Ashwini Sethupathy Ann Jorunn Sandstå Gunn-Janne Paulsen Thor Ueland Annika E. Michelsen Pål Aukrust Jan‐Erik Berdal Ingunn Melkeraaen Merete Moen Tollefsen J. Andreassen Jannicke Dokken Karl Erik Müller Bjørn Martin Woll Hanne Opsand Mette Bogen Linn-Therese Rød Trude Steinsvik Bjørn Åsheim-Hansen Randi Haukaas Bjerkreim Åse Berg Solfrid Moen Stina Kvalheim Kristian Strand Berit Gravrok Vegard Skogen Elias Myrvoll Lorentzen Simen W. Schive L. Rossvoll Hedda Hoel Simon Engebråten Mia Schie Martinsson Monica Thallinger

Abstract Background Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused specifically on severe/critical COVID, including vaccinated participants. Methods Bari-SolidAct is a phase-3, multicentre, randomised, double-blind, trial, enrolling participants from June 3, 2021 to March 7, 2022, stopped prematurely for external evidence. Patients COVID-19 were randomised 4 mg once daily or placebo, added standard of care. The primary...

10.1186/s13054-022-04205-8 article EN cc-by Critical Care 2023-01-10

Invasive pulmonary aspergillosis (IPA) is a complication of respiratory bacterial and viral infections such as coronavirus disease 2019 (COVID-19).In University Hospital La Paz (Madrid, Spain), we reviewed the clinical demographic characteristics 10 patients with positive severe acute syndrome 2 (SARS-CoV-2) PCR Aspergillus spp. isolate in samples. We also recovered results galactomannan tests serum and/or bronchoalveolar lavage (BAL) samples.Eight male two female from 51 to 76 years were...

10.1111/myc.13155 article EN Mycoses 2020-08-04

Treatment of hepatitis B virus (HBV) with lamivudine may not completely suppress viral replication and often fails as a result resistance. Tenofovir is new HIV inhibitor further activity against HBV, which was explored in 12 HBV/HIV-co-infected patients detectable levels serum HBV-DNA, despite receiving lamivudine-containing antiretroviral regimen. Lamivudine-resistance mutations were found HBV from seven patients. HBV-DNA dropped median 3.78 logs baseline to 24 weeks. very effective at...

10.1097/00002030-200211220-00023 article EN AIDS 2002-11-01

Background Human metapneumovirus (HMPV) has an important etiological role in acute lower respiratory infections children under five years. Our objectives were to estimate the relative contribution of HMPV hospitalization with infection, define clinical and epidemiological features single multiple infections, compare syncytial virus (HRSV), rhinovirus (HRV), adenovirus human bocavirus same population. Methods findings A prospective study performed on all less than 14 years age a tract disease...

10.1371/journal.pone.0173504 article EN cc-by PLoS ONE 2017-03-16

Introduction: The concurrency of both, acute stroke and myocardial infarction in normal conditions, outside the pandemic is rare. Coagulopathy has been associated with inflammatory phase coronavirus disease (COVID-19) might be involved this concurrency. Cases Report: We describe 2 patients previous mild or no symptoms COVID-19, admitted for recent/simultaneous whom admission polymerase chain reaction was negative but serologic testing diagnosed COVID-19. In these patients, concurrent could...

10.1097/nrl.0000000000000311 article EN The Neurologist 2021-05-01

Abstract Ventriculitis is a complication of meningitis (community-acquired or nosocomial) other central nervous system (CNS) infections such as brain abscess. They are associated with different spectrum microorganisms, from resistant gram-negative bacilli to staphylococci, that can lead serious illness high mortality. Difficult-to-treat resistance (DTR) may increase 20% deaths respective susceptible isolates the same bacteria. We present first report clinical cured case DTR Pseudomonas...

10.1093/ofid/ofac391 article EN cc-by-nc-nd Open Forum Infectious Diseases 2022-08-01

The immune suppression caused by HIV infection accelerates the course of liver disease chronic hepatitis B virus (HBV) infection. We assessed outcome HIV/HBV-coinfected patients exposed to highly active antiretroviral therapy (HAART) including anti-HBV drugs. Baseline and follow-up plasma HBVDNA HIV-RNA levels, HBV serological markers, CD4 counts were longitudinally evaluated in all HBsAg(+) individuals with on regular at an urban reference clinic. Out 79 carriers identified, 39 (50%)...

10.1089/aid.2006.22.842 article EN AIDS Research and Human Retroviruses 2006-09-01

Bezlotoxumab is marketed for the prevention of recurrent Clostridioides difficile infection (rCDI). Its high cost could be determining its prescription to a different population than that represented in clinical trials. The objective study was verify effectiveness and safety bezlotoxumab preventing rCDI investigate factors related failure real world. A retrospective, multicentre cohort patients treated with Spain conducted. We compared characteristics those pivotal MODIFY assessed recurrence...

10.3390/jcm10010002 article EN Journal of Clinical Medicine 2020-12-22

The SARS-CoV-2 pandemic might have increased the risks of healthcare-associated infections (HAIs); however, several studies HAI such as urinary tract (UTIs) and catheter-associated (CAUTIs) shown contradictory results. aim this study is to assess clinical features UTIs bacterial isolates from urine samples hospitalized COVID-19 patients. We conducted a retrospective observational including 87 patients with admitted our centre. Bacterial presented were 87: 9 (10.3%) community-acquired...

10.3390/jcm11071815 article EN Journal of Clinical Medicine 2022-03-25

Background: Lopinavir/ritonavir (Kaletra) is the latest available protease inhibitor (PI). It has shown greater potency than former PIs in phase II/III trials, either naive or PI-experienced patients being for nonnucleoside reverse transcriptase inhibitors (NNRTIs). Method: We analyzed first 138 recruited during expanded access program an HIV/AIDS reference center. Only who had significant past exposure to all three different antiretroviral drug families and were failing their current...

10.1310/h5jn-mfg3-g35k-qx9j article EN HIV Clinical Trials 2002-08-01

Background. Because most infections caused by carbapenemase-producing Enterobacteriaceae (CPE) begin during hospitalization, there are limited data about community-onset (CO) CPE. Our aim is to describe the frequency of CO CPE as well clinical features bloodstream (CO-BSIs). Methods. This study includes retrospective case series in a tertiary hospital from January 2010 July 2014. Any sample with positive culture for that had been ordered primary care doctors or at emergency room (ER) were...

10.1093/ofid/ofw136 article EN cc-by-nc-nd Open Forum Infectious Diseases 2016-01-01

Both fidaxomicin and bezlotoxumab (used in combination with an antibiotic against Clostridioides difficile) achieve reductions recurrence rates of C. difficile infection (CDI). However, the two strategies have never been compared.Data from retrospective cohorts 'real-life' use a standard anti-C. were used to compare both strategies. Since not identical, we propensity score analysis.Three hundred patients included: 244 cohort 78 cohort. A history renal failure or immunosuppression was more...

10.1093/jac/dkac106 article EN Journal of Antimicrobial Chemotherapy 2022-03-18

ABSTRACT Epstein‐Barr virus (EBV) is a herpesvirus capable of establishing lifelong latent infections, leading to wide spectrum diseases. It can affect multiple organs, including the gastrointestinal tract, typically through lymphoproliferative syndromes or gastric cancer, while acute disease rare and poorly understood. Two cases EBV‐induced colitis in kidney transplant recipients were described. Additionally, scoping review literature was conducted identify all reported EBV infection...

10.1002/jmv.70121 article EN Journal of Medical Virology 2024-12-01

Background Linezolid has good penetration to the meninges and could be an alternative for treatment of Staphylococcus aureus meningitis. We assessed efficacy safety linezolid therapy this infection.Methods Retrospective multicenter cohort study 26 adults treated with linezolid, derived from a 350 cases S. meningitis diagnosed at 11 university hospitals in Spain (1981-2015).Results There were 15 males (58%) mean age was 47.3 years. Meningitis postoperative 21 (81%) patients. The infection...

10.1080/23744235.2020.1789212 article EN Infectious Diseases 2020-07-10
Coming Soon ...